These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 9494967)

  • 41. Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer.
    Calabrese LH; Caporali R; Blank CU; Kirk AD
    J Autoimmun; 2020 Dec; 115():102546. PubMed ID: 32980229
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Liver auto-immunology: the paradox of autoimmunity in a tolerogenic organ.
    Invernizzi P
    J Autoimmun; 2013 Oct; 46():1-6. PubMed ID: 24012346
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The current and future outlook in immunosuppressive therapy for children].
    Goţia S; Ionescu C
    Rev Med Chir Soc Med Nat Iasi; 1995; 99(1-2):35-42. PubMed ID: 9524654
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunosuppressive therapy of autoimmune diseases.
    Bach JF
    Immunol Today; 1993 Jun; 14(6):322-6. PubMed ID: 8104411
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases.
    Bruno V; Battaglia G; Nicoletti F
    Neurol Sci; 2011 Jan; 31 Suppl 3():283-8. PubMed ID: 20644974
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selective manipulation of the immune response in vivo by monoclonal antibodies.
    Seaman WE; Wofsy D
    Annu Rev Med; 1988; 39():231-41. PubMed ID: 3285774
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The basis of autoimmunity: Part I. Mechanisms of aberrant self-recognition.
    Theofilopoulos AN
    Immunol Today; 1995 Feb; 16(2):90-8. PubMed ID: 7888073
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of the interleukin-6 signaling pathway: a strategy to induce immune tolerance.
    Zhang C; Zhang X; Chen XH
    Clin Rev Allergy Immunol; 2014 Oct; 47(2):163-73. PubMed ID: 24647663
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cellular and molecular mechanisms of autoimmune disease.
    Bolon B
    Toxicol Pathol; 2012; 40(2):216-29. PubMed ID: 22105648
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regulation of autoimmunity.
    Kumar V; Sercarz EE
    Curr Opin Immunol; 1991 Dec; 3(6):888-95. PubMed ID: 1793531
    [TBL] [Abstract][Full Text] [Related]  

  • 51. T cell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction.
    Sayegh MH; Turka LA
    J Am Soc Nephrol; 1995 Oct; 6(4):1143-50. PubMed ID: 8589280
    [TBL] [Abstract][Full Text] [Related]  

  • 52. T cell metabolism and susceptibility to autoimmune diseases.
    Galgani M; De Rosa V; Matarese G
    Mol Immunol; 2015 Dec; 68(2 Pt C):558-63. PubMed ID: 26265113
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The evolution of the immunobiology of co-stimulatory pathways: clinical implications.
    Trikudanathan S; Sayegh MH
    Clin Exp Rheumatol; 2007; 25(5 Suppl 46):S12-21. PubMed ID: 17977484
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunology of renal transplantation rejection.
    Hall BM
    Med J Aust; 1982 Oct; 2(9):422-4, 425. PubMed ID: 6757691
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunology at the maternal-fetal interface: lessons for T cell tolerance and suppression.
    Mellor AL; Munn DH
    Annu Rev Immunol; 2000; 18():367-91. PubMed ID: 10837063
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deal watch: Boosting TRegs to target autoimmune disease.
    Nat Rev Drug Discov; 2011 Aug; 10(8):566. PubMed ID: 21804584
    [No Abstract]   [Full Text] [Related]  

  • 57. P-glycoprotein--a novel therapeutic target for immunomodulation in clinical transplantation and autoimmunity?
    Pendse S; Sayegh MH; Frank MH
    Curr Drug Targets; 2003 Aug; 4(6):469-76. PubMed ID: 12866661
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Monoclonal antibody-based strategies in autoimmunity and transplantation.
    Chatenoud L
    Methods Mol Med; 2005; 109():297-328. PubMed ID: 15585929
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Coronin-1a is a potential therapeutic target for activated T cell-related immune disorders.
    Xu XJ; Tang YM
    APMIS; 2015 Jan; 123(1):89-91. PubMed ID: 24862375
    [No Abstract]   [Full Text] [Related]  

  • 60. Immunosuppressive Medications.
    Wiseman AC
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):332-43. PubMed ID: 26170177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.